(203) 815-5782
balmassian@carogencorp.com
CaroGen Corp
About Us

CaroGen Highlights

Novel Platform: AVIDIO (Artificial Virus for Infectious Diseases and Immuno-Oncology)
Two Lead Clinical Candidates Progressing Toward IND (CARG-2020, CARG-201)
Broad and Growing Patent Portfolio with issued composition of matter for the platform and method of use for HBV and oncology
Awarded over $10 million in NIH and Department of Defense grants (2018-2025)
AVIDIO Platform
CARG-2020
CARG-201

AVIDIO Platform

Read More

Oncology: CARG-2020

Read More

Infectious Disease: CARG-201

Read More
CaroGen Corp
OUR TEAM

Senior Management and Founders

CaroGen Corp

Bijan Almassian, PhD

Co-Founder, President & CEO Board of Directors

CaroGen Corp

Deborah Church, MD

Chief Medical Officer

CaroGen Corp

John Rose, PhD

Co-Founder and Chairman of the SAB

CaroGen Corp

Michael Robek, PhD

Co-Founder, Member of SAB

See all team members
OUR PRESS RELEASES

CaroGen News

CaroGen Corp

CaroGen’s CARG-2020 Preclinical Data on Ovarian Cancer Immunotherapy to be Presented Orally at the Society of Gynecologic Oncology Annual Meeting

CaroGen Corp

CaroGen Management to Speak at The World Vaccine Immunotherapy Congress

Farmington, CT, September 5, 2022– CaroGen Corporation (https://carogencorp.com), a developer of trans-formative immunotherapies for cancer and infectious diseases, today announced that Bijan Almassian, PhD, President & CEO, and Timur Yarovinsky, MD, PhD, Vice President of Discovery

CaroGen Corp

Bijan Almassian, PhD. on LinkedIn: CaroGen in pact with NIH to develop flu vaccine – BioCT | 21 comments

We are honored to be working with NIAID/NIH scientists to develop a universal influenza vaccine.

Explore all latest News.
CaroGen Corporation CaroGen Corporation (203) 815-5782 balmassian@carogencorp.com